Commodore Capital CTMX Position
Active8-Fund ConvergenceCommodore Capital held their position in CytomX Therapeutics Inc. (CTMX) in Q4 2025, holding $32.8M worth of shares across 7,692,300 shares.
The position was first reported in Q2 2025 and has been tracked across 3 quarterly 13F filings.
CTMX is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 12.4% of float with 7.4 days to cover, indicating significant bearish positioning against Commodore's long thesis.
About CytomX Therapeutics Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Full company profile →Short Interest
12.4%
7.4 days to cover
Commodore Capital CTMX Position History
Frequently Asked Questions
Does Commodore Capital own CTMX?
Yes. As of Q4 2025, Commodore Capital holds 7,692,300 shares of CytomX Therapeutics Inc. (CTMX) valued at $32.8M. This data comes from their SEC 13F filing.
How many hedge funds own CTMX?
8 specialist biotech hedge funds currently hold CTMX, including Perceptive Advisors, Tang Capital Management, OrbiMed Advisors and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Commodore Capital first buy CTMX?
Commodore Capital's position in CTMX was first reported in Q2 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Commodore Capital's CTMX position increasing or decreasing?
Commodore Capital held their CTMX position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CTMXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Commodore CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →